125 related articles for article (PubMed ID: 19179773)
21. Acute effects of nebulised epoprostenol in pulmonary hypertension due to systemic sclerosis.
Parameswaran K; Purcell I; Farrer M; Holland C; Taylor IK; Keaney NP
Respir Med; 1999 Feb; 93(2):75-8. PubMed ID: 10464856
[TBL] [Abstract][Full Text] [Related]
22. Continuous epoprostenol therapy and septal defect closure in a patient with severe pulmonary hypertension.
Hirabayashi A; Miyaji K; Akagi T
Catheter Cardiovasc Interv; 2009 Apr; 73(5):688-91. PubMed ID: 19133673
[TBL] [Abstract][Full Text] [Related]
23. Long-term outcomes of epoprostenol therapy in sarcoid associated pulmonary hypertension.
Abston E; Moll M; Hon S; Govender P; Berman J; Farber H
Sarcoidosis Vasc Diffuse Lung Dis; 2020; 37(2):184-191. PubMed ID: 33093782
[TBL] [Abstract][Full Text] [Related]
24. Effects of prostacyclin on the pulmonary vascular tone and cardiac contractility of patients with pulmonary hypertension secondary to end-stage heart failure.
Montalescot G; Drobinski G; Meurin P; Maclouf J; Sotirov I; Philippe F; Choussat R; Morin E; Thomas D
Am J Cardiol; 1998 Sep; 82(6):749-55. PubMed ID: 9761085
[TBL] [Abstract][Full Text] [Related]
25. Long-term follow-up of portopulmonary hypertension: effect of treatment with epoprostenol.
Fix OK; Bass NM; De Marco T; Merriman RB
Liver Transpl; 2007 Jun; 13(6):875-85. PubMed ID: 17539008
[TBL] [Abstract][Full Text] [Related]
26. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival.
Sitbon O; Humbert M; Nunes H; Parent F; Garcia G; Hervé P; Rainisio M; Simonneau G
J Am Coll Cardiol; 2002 Aug; 40(4):780-8. PubMed ID: 12204511
[TBL] [Abstract][Full Text] [Related]
27. Aerosolized iloprost therapy could not replace long-term IV epoprostenol (prostacyclin) administration in severe pulmonary hypertension.
Schenk P; Petkov V; Madl C; Kramer L; Kneussl M; Ziesche R; Lang I
Chest; 2001 Jan; 119(1):296-300. PubMed ID: 11157622
[TBL] [Abstract][Full Text] [Related]
28. Progressive portopulmonary hypertension after liver transplantation treated with epoprostenol.
Rafanan AL; Maurer J; Mehta AC; Schilz R
Chest; 2000 Nov; 118(5):1497-500. PubMed ID: 11083710
[TBL] [Abstract][Full Text] [Related]
29. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension.
McLaughlin VV; Genthner DE; Panella MM; Rich S
N Engl J Med; 1998 Jan; 338(5):273-7. PubMed ID: 9445406
[TBL] [Abstract][Full Text] [Related]
30. Inhaled epoprostenol (prostacyclin) and pulmonary hypertension before cardiac surgery.
Haché M; Denault A; Bélisle S; Robitaille D; Couture P; Sheridan P; Pellerin M; Babin D; Noël N; Guertin MC; Martineau R; Dupuis J
J Thorac Cardiovasc Surg; 2003 Mar; 125(3):642-9. PubMed ID: 12658208
[TBL] [Abstract][Full Text] [Related]
31. A prospective, randomized study of inhaled prostacyclin versus nitric oxide in patients with residual pulmonary hypertension after pulmonary endarterectomy.
Abe S; Ishida K; Masuda M; Ueda H; Kohno H; Matsuura K; Tamura Y; Watanabe M; Matsumiya G
Gen Thorac Cardiovasc Surg; 2017 Mar; 65(3):153-159. PubMed ID: 27783213
[TBL] [Abstract][Full Text] [Related]
32. Continuous intravenous epoprostenol in pulmonary hypertension: the Israel experience.
Bendayan D; Fink G; Aravot D; Ygla M; Bendov I; Bliden L; Nir A; Kramer MR
Isr Med Assoc J; 2002 Apr; 4(4):255-8. PubMed ID: 12001697
[TBL] [Abstract][Full Text] [Related]
33. Treatment of canine pulmonary hypertension: effects of norepinephrine and isoproterenol on pulmonary vascular pressure-flow characteristics.
Ducas J; Duval D; Dasilva H; Boiteau P; Prewitt RM
Circulation; 1987 Jan; 75(1):235-42. PubMed ID: 3791605
[TBL] [Abstract][Full Text] [Related]
34. Sarcoidosis-associated pulmonary hypertension: outcome with long-term epoprostenol treatment.
Fisher KA; Serlin DM; Wilson KC; Walter RE; Berman JS; Farber HW
Chest; 2006 Nov; 130(5):1481-8. PubMed ID: 17099027
[TBL] [Abstract][Full Text] [Related]
35. Effects of epoprostenol on right ventricular hypertrophy and dilatation in pulmonary hypertension.
Roeleveld RJ; Vonk-Noordegraaf A; Marcus JT; Bronzwaer JG; Marques KM; Postmus PE; Boonstra A
Chest; 2004 Feb; 125(2):572-9. PubMed ID: 14769740
[TBL] [Abstract][Full Text] [Related]
36. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial.
Simonneau G; Rubin LJ; Galiè N; Barst RJ; Fleming TR; Frost AE; Engel PJ; Kramer MR; Burgess G; Collings L; Cossons N; Sitbon O; Badesch DB;
Ann Intern Med; 2008 Oct; 149(8):521-30. PubMed ID: 18936500
[TBL] [Abstract][Full Text] [Related]
37. Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus.
Robbins IM; Gaine SP; Schilz R; Tapson VF; Rubin LJ; Loyd JE
Chest; 2000 Jan; 117(1):14-8. PubMed ID: 10631192
[TBL] [Abstract][Full Text] [Related]
38. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial.
Badesch DB; Tapson VF; McGoon MD; Brundage BH; Rubin LJ; Wigley FM; Rich S; Barst RJ; Barrett PS; Kral KM; Jöbsis MM; Loyd JE; Murali S; Frost A; Girgis R; Bourge RC; Ralph DD; Elliott CG; Hill NS; Langleben D; Schilz RJ; McLaughlin VV; Robbins IM; Groves BM; Shapiro S; Medsger TA
Ann Intern Med; 2000 Mar; 132(6):425-34. PubMed ID: 10733441
[TBL] [Abstract][Full Text] [Related]
39. Comparative acute effects of adenosine and prostacyclin in primary pulmonary hypertension.
Nootens M; Schrader B; Kaufmann E; Vestal R; Long W; Rich S
Chest; 1995 Jan; 107(1):54-7. PubMed ID: 7813311
[TBL] [Abstract][Full Text] [Related]
40. Long-term treatment with oral sildenafil in addition to continuous IV epoprostenol in patients with pulmonary arterial hypertension.
Stiebellehner L; Petkov V; Vonbank K; Funk G; Schenk P; Ziesche R; Block LH
Chest; 2003 Apr; 123(4):1293-5. PubMed ID: 12684325
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
